An in vitro study of AML showed that abrogation of CD200-CD200R interaction enhances the T cell-stimulatory capacity of DCs [100], whereas inhibition of CD200-CD200R interaction was already investigated in clinical trial phase I/II in patients with relapsing or refractory B cell chronic lymphocytic leukemia or multiple myeloma. The gene discussed is CD200R1; the disease is plasma cell myeloma.